Sero-prevalence of HIV infection among tuberculosis patients in a rural tuberculosis referral clinic in northern Nigeria

Co-infection with Human Immunodeficiency virus (HIV) and Mycobacterium tuberculosis the causative agent of Tuberculosis (TB), has been referred to as the “cursed duet” as a result of the attendant morbidity and mortality due to their synergistic actions. This study was carried out to determine the prevalence of HIV infection among Tuberculosis (TB) confirmed patients on admission at a TB referral centre. The association of HIV prevalence with gender and age as risk factors was also determined. Blood samples were collected by venipuncture from 257 TB patients and their HIV status determined. Viral antibody detection was carried out using ELISA kits which detected both HIV-1 and HIV-2 and confirmed by Western blot. Of the 257 patients screened, 44.20% (106) were HIV positive. The prevalence of co-infection was higher among the female (44.82%) than the male (38.30%) patients and highest among those aged 21-40 years old (45.30%). Co-infection was found to be statistically highly associated with gender and age (p<0.05). A very high prevalence of HIV infection was reported in this study among patients that were on admission on the grounds that they had only TB. It is therefore important to screen for HIV among all TB patients

Burden of disease and circulating serotypes of rotavirus infection in sub-Saharan Africa: systematic review and meta-analysis.

Two new rotavirus vaccines have recently been licensed in many countries. However, their efficacy has only been shown against certain serotypes commonly circulating in Europe, North America, and Latin America, but thought to be globally important. To assess the potential impact of these vaccines in sub-Saharan Africa, where rotavirus mortality is high, knowledge of prevalent types is essential because an effective rotavirus vaccine is needed to protect against prevailing serotypes in the community. We did two systematic reviews and two meta-analyses of the most recent published data on the burden of rotavirus disease in children aged under 5 years and rotavirus serotypes circulating in countries in sub-Saharan Africa. Eligible studies were selected from PubMed/Medline, Cochrane Library, EmBase, LILACS, Academic Search Premier, Biological Abstracts, ISI Web of Science, and the African Index Medicus. Depending on the heterogeneity, DerSimonian-Laird random-effects or fixed-effects models were used for meta-analyses. Geographical variability in rotavirus burden within countries in sub-Saharan Africa is substantial, and most countries lack information on rotavirus epidemiology. We estimated that annual mortality for this region was 243.3 (95% CI 187.6-301.7) deaths per 100,000 under 5 years (ie, a total of 300,000 children die of rotavirus infection in this region each year). The most common G type detected was G1 (34.9%), followed by G2 (9.1%), and G3 (8.6%). The most common P types detected were P[8] (35.5%) and P[6] (27.5%). Accurate information should be collected from surveillance based on standardised methods in these countries to obtain comparable data on the burden of disease and the circulating strains to assess the potential impact of vaccine introduction

Estimating the burden of rubella virus infection and congenital rubella syndrome through a rubella immunity assessment among pregnant women in the Democratic Republic of the Congo: Potential impact on vaccination policy.

BACKGROUND: Rubella-containing vaccines (RCV) are not yet part of the Democratic Republic of the Congo's (DRC) vaccination program; however RCV introduction is planned before 2020. Because documentation of DRC's historical burden of rubella virus infection and congenital rubella syndrome (CRS) has been minimal, estimates of the burden of rubella virus infection and of CRS would help inform the country's strategy for RCV introduction. METHODS: A rubella antibody seroprevalence assessment was conducted using serum collected during 2008-2009 from 1605 pregnant women aged 15-46years attending 7 antenatal care sites in 3 of DRC's provinces. Estimates of age- and site-specific rubella antibody seroprevalence, population, and fertility rates were used in catalytic models to estimate the incidence of CRS per 100,000 live births and the number of CRS cases born in 2013 in DRC. RESULTS: Overall 84% (95% CI 82, 86) of the women tested were estimated to be rubella antibody seropositive. The association between age and estimated antibody seroprevalence, adjusting for study site, was not significant (p=0.10). Differences in overall estimated seroprevalence by study site were observed indicating variation by geographical area (p⩽0.03 for all). Estimated seroprevalence was similar for women declaring residence in urban (84%) versus rural (83%) settings (p=0.67). In 2013 for DRC nationally, the estimated incidence of CRS was 69/100,000 live births (95% CI 0, 186), corresponding to 2886 infants (95% CI 342, 6395) born with CRS. CONCLUSIONS: In the 3 provinces, rubella virus transmission is endemic, and most viral exposure and seroconversion occurs before age 15years. However, approximately 10-20% of the women were susceptible to rubella virus infection and thus at risk for having an infant with CRS. This analysis can guide plans for introduction of RCV in DRC. Per World Health Organization recommendations, introduction of RCV should be accompanied by a campaign targeting all children 9months to 14years of age as well as vaccination of women of child bearing age through routine services

Seroprevalence of Hepatitis B and C Viruses among Human Immunodeficiency Virus Infected Patients Accessing Healthcare in Federal Medical Centre, Keffi, Nigeria

Infections of Hepatitis B and C viruses among seropositive Human immunodeficiency virus patients are a growing public health problem in Sub Saharan Africa characterized by unaffordable treatment, severe morbidity and associated mortality. This study was aimed at evaluating the seroprevalence of Hepatitis B and C viruses among HIV infected patients accessing health care at Federal Medical Centre, Keffi, Nigeria. The cross-sectional study took place between May-July 2016. A total of 200 blood samples were collected from HIV patients after informed consent and self-administered questionnaires were completed. The samples were centrifuged and the serum screened for HBV and HCV using the immunochromatographic technique. A general prevalence of infection with hepatitis B and C viruses in the study population was 17.5%. The prevalence of HBV infection was 12.5% while HCV was 5.0%. Females have higher infection rates for both viruses (p > 0.05). HBV infection was highest among those aged 20-29 years (14.3%) and lowest among those aged 30-39 years (6.5%). HCV infection was highest among those aged > 40 years (8.7%) and least among those aged 30-39 years (0.0%). Infection rates with blood transfusion, smoking habit, scarification marks and alcohol intake as risk factors were more for HBV than HCV (p > 0.05). The HIV/HBV and HIV/HCV coinfection prevalence of 12.5% and 5.0% respectively is a cause for concern. This finding underscores the urgent need for more proactive HBV immunization programs and screening of HIV patients for HBV and HCV before and even during antiretroviral therapy. Health education against these silent killers should also be advocated

AIDS-related mycoses: the way forward.

The contribution of fungal infections to the morbidity and mortality of HIV-infected individuals is largely unrecognized. A recent meeting highlighted several priorities that need to be urgently addressed, including improved epidemiological surveillance, increased availability of existing diagnostics and drugs, more training in the field of medical mycology, and better funding for research and provision of treatment, particularly in developing countries